[CAS NO. 1187187-10-5] AN3199
PRODUCTS SPECIFICATIONS [1187187-10-5]
DESCRIPTION [1187187-10-5]
Overview
| MDL | MFCD29924720 |
|---|---|
| Molecular Weight | 327.14 |
| Molecular Formula | C17H18BNO5 |
| SMILES | O=C(C1=CC=C(OC2=CC=C(B(O)OC3)C3=C2)N=C1)OCCCC |
Summary
IC50 & Target
|
PDE4 94.5 nM (IC 50 ) |
In Vitro
AN3199 (compound 11) (1 h) disappears (98.0%) is mainly converts to corresponding acid (76.6) in mouse plasma [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 305.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.0568 mL | 15.2840 mL | 30.5680 mL |
| 5 mM | 0.6114 mL | 3.0568 mL | 6.1136 mL |
| 10 mM | 0.3057 mL | 1.5284 mL | 3.0568 mL |
References
- [1] Zhang YK, et al. Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2270-4.
- [2] Akama Tsutomu, et al. Preparation of boron-containing small molecules as anti-inflammatory agents. From PCT Int. Appl. (2009), WO 2009111676 A2 20090911.
